EDGAR·FLOW

Immunovant, Inc. — Form 8-K

Filed November 9, 2026 · analyzed by the 8-K Agent
8-K ▲ Likely positive significance 72/100
What the filing says
Immunovant's lead candidate IMVT-1402 600 mg achieved the primary endpoint of ACR20 response in Period 2 of its potentially registrational difficult-to-treat rheumatoid arthritis (D2T RA) trial: 92.5% vs. 75.6% placebo (p=0.0139), with 117 participants randomized (40 on 600mg, 36 on 300mg, 41 placebo). The company halted further development in Sjögren's disease beyond the ongoing Phase 2 trial. FDA discussions are planned for late 2026 on the RA registrational path. Cash position: $722.3M as of September 30, 2026; 206,785,540 shares outstanding.
Why this rating

Positive phase 2b data supports potential commercial pathway; cash runway sufficient for GD launch; modest endpoint (ACR20, not powered secondary endpoints); no major M&A or revenue catalyst yet imminent.

Tradability signal
NO TRADE

No trade: only ~$0k traded in the last 30 min — too illiquid to enter and exit. (Filing arrived outside market hours — evaluated at the next open with a live quote.)

Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.

Price action (we called it positive)
before filing · preread
$35.85 ▲ 8.06%
at our read · unknown
$33.17
+10 min · unknown
$34.86 ▲ 5.08%
+30 min · unknown
$35.31 ▲ 6.45%
+1 hr · unknown
$34.98 ▲ 5.44%
+4 hrs · unknown
$33.94 ▲ 2.31%

The stock had already moved -7.46% between hitting EDGAR and our read finishing — deltas above are measured from our read.

Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →

View original filing on SEC.gov ↗ IMVT · stock on Yahoo Finance ↗

See more from November 9, 2026.

EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.